Medical/Pharmaceuticals
I-Mab Announces Voluntary Lock-ups by Key Shareholders and Senior Management for Long-Term Commitment
SHANGHAI and GAITHERSBURG, Md., March 31, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the Company's key shareholders including CBC Grou...
2022-03-31 20:00
2025
HOYA Group Appoints Rainer Burkard as Global President of PENTAX Medical
TOKYO, March 31, 2022 /PRNewswire/ -- PENTAX Medical, a division of HOYA Group,
has announced the appointment ofRainer Burkard to the position of Global
President of PENTAX Lifecare Division (PENTAX Medical) as ofApril 1st, 2022.
2022-03-31 20:00
4100
China Pharma Holdings, Inc. Reports Fiscal Year 2021 Financial Results
HAIKOU, China, March 31, 2022 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based inChina, today announced financial results for the fiscal...
2022-03-31 20:00
4520
Tai Chi Training Can Effectively Improve Parkinson's Disease and Mild Cognitive Impairment
HONG KONG, March 31, 2022 /PRNewswire/ -- The latest research shows that Tai Chi training is conducive to the treatment of Parkinson's disease and the prevention of Alzheimer's disease. Professor Shengdi Chen from the Neurology Department of Ruijin Hospital, Shanghai Jiao Tong University School o...
2022-03-31 18:15
5364
Brii Bio Presents New Data on BRII-835 (VIR-2218) in Chinese Patients with Chronic Hepatitis B at APASL 2022
New data demonstrate BRII-835 (VIR-2218) was well tolerated with notable
reductions in serum HBsAgobserved in the Chinese patients infected with chronic
hepatitis B
DURHAM, N.C. and BEIJING, March 31, 2022 /PRNewswire/ -- Brii Biosciences
2022-03-31 18:05
4433
Novavax Submits Request to Expand Conditional Marketing Authorization of COVID-19 Vaccine in the European Union to Adolescents (Ages 12-17)
* If granted, Nuvaxovid™ COVID-19 Vaccine (recombinant, adjuvanted) would be the first protein-based option for adolescents aged 12-17 years inEurope GAITHERSBURG, Md., March 31, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializi...
2022-03-31 18:00
4595
Airway Therapeutics Announces First Patient Dosed in Phase 1b Trial of AT-100 in Preterm Infants at Risk for Bronchopulmonary Dysplasia (BPD)
Novel preventative AT-100 offers potential to reduce incidence and severity of serious respiratory disease BPD, improving outcomes in very preterm infants MARIETTA, Ga., March 31, 2022 /PRNewswire/ -- Airway Therapeutics, Inc. (Airway), a biopharmaceutical company developing a new class of biolog...
2022-03-31 17:00
4027
CBC Group-backed Hasten Biopharma successfully completes acquisition of five cardiovascular and metabolism drugs from Takeda
* CBC Group continues to expand its global healthcare ecosystem to fulfil unmet medical needs * Hasten fast-tracks transformative medicines for patients in China SHANGHAI, March 31, 2022 /PRNewswire/ -- Hasten Biopharmaceutic Co., Ltd (China) ("Hasten") today announced that it has acquired a ...
2022-03-31 15:05
2806
JW Therapeutics Announces IND Approval for the Pivotal Clinical Trial of Carteyva® in Second-line Large B-Cell Lymphoma
SHANGHAI, March 31, 2022 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent, innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, announced that it has received the Investigational New Drug (IND) clearance from the Nation...
2022-03-31 12:20
4371
CStone announces first patient enrollment in the U.S. in the Phase 1 clinical trial of CS5001, a potential global best-in-class ROR1-targeting ADC
* Commencement of the first-in-human clinical trial of CS5001 marks another key milestone for CStone's Pipeline 2.0 * Global development of CS5001 is conducted in the form of a multi-regional clinical trial, with sites initiated in the US andAustralia, and an IND application accepted by the ...
2022-03-31 08:02
4633
Everest Medicines Submits New Drug Application in Hong Kong for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer
SHANGHAI, March 31, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products to address critical unmet needs inAsia Pacific markets, announced today that it has submitted a New Drug Applicat...
2022-03-31 08:00
5357
Change of Composition of the Telix Board of Directors
* Non-Executive Director Oliver Buck to retire at the Annual General Meeting * Tiffany Olson, experienced U.S.-based pharma executive appointed as independent Non-Executive Director MELBOURNE, Australia and INDIANAPOLIS, March 31, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, T...
2022-03-31 07:11
3139
Simulare Medical, a Division of Smile Train, Announces Patent-Pending Bilateral Cleft Lip and Palate Simulator
New Simulator to Accelerate the Learning Curve in Cleft Reconstructive Surgical Training & Ultimately Further Care for Cleft-Affected Children FORT WORTH, Texas, March 31, 2022 /PRNewswire/ -- Simulare Medical, a Division of Smile Train, Inc., has launched the newest innovation in its growing li...
2022-03-31 07:05
1905
LifeTech Scientific Corporation（1302.HK） Announces 2021 Annual Results
Excluding certain non-recurring items, the net profit attributable to owners of the Company increased by 76.8% to RMB 324.0million SHENZHEN, China, March 30, 2022 /PRNewswire/ -- LifeTech Scientific Corporation (LifeTech, 1302.HK), a leading company specialized in minimally invasive interventio...
2022-03-31 03:27
4140
Keymed Biosciences Releases 2021 Annual Results
CHENGDU, China, March 30, 2022 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX Code: 02162) released 2021 annual results. BUSINESS HIGHLIGHTS On July 8, 2021, Keymed was listed on the HKEX. During the Reporting Period, the Company continued proceeding the R&D of products and made the following p...
2022-03-30 23:41
3061
Broncus Medical (02216.HK) Announces Annual Results for 2021: Operating revenue for 2021 increased 234.2% year-on-year, while product development and commercialization are steadily advancing.
HANGZHOU, China, March 30, 2022 /PRNewswire/ -- On March 29, 2022, Broncus Medical (02216.HK), the leader in precision interventional treatment for lung diseases inChina, announced its annual results announcement for the year ended December 31, 2021. During the period, the Group earned revenue of...
2022-03-30 21:58
3996
Symbiance announces the launch of SimpleStats, an application for statistical analysis and reporting of clinical data
PRINCTON, N.J., March 30, 2022 /PRNewswire/ -- SimpleStats (www.SimpleStats.ai) is designed to help Pharmaceutical/Biotech industries to automate statistical analysis and reporting of clinical data! Symbiance announced the launch of its Artificial Intelligence (AI) powered product SimpleStats. T...
2022-03-30 21:00
2162
Transcenta Announces Presentation of Preclinical Data of TST005 at the 2022 American Association for Cancer Research (AACR) Annual Meeting
SUZHOU, China, March 30, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces the preclinical data...
2022-03-30 19:28
3037
FDA approves CartiHeal's Implant for the Treatment of Cartilage and Osteochondral Defects
Approval is based on results of a multicenter, randomized, open-labeled and controlled IDE clinical study that demonstrated the superiority of Agili-C™ implant to the current surgical standard of care, debridement and microfracture in the knee joint KFAR SABA, Israel, March 30, 2022 /PRNewswire/...
2022-03-30 19:00
2112
Ascletis Announces Completion of Patient Enrollment in Phase II Clinical Trial of ASC42, an In-House Developed, Best-in-Class FXR Agonist for Chronic Hepatitis B Indication
--Compared to the placebo cohort, both 10 mg and 15 mg ASC42 cohorts are safe and well tolerated to date. Most of adverse events are grade 1 or 2. --ASC42 is a novel anti-viral candidate for HBV functional cure through inhibiting the transcription of HBV cccDNA into HBV RNA and reducing the HBV ...
2022-03-30 18:26
3507
Week's Top Stories
Most Reposted
OceanaGold Reports Third Quarter 2026 Results
[Picked up by 1141 media titles]
2026-11-05 06:52Royal Bank of Canada announces agreement to acquire Yarra Capital Management
[Picked up by 1141 media titles]
2026-11-09 21:00Algolia Powers Orange with AI Agents for Billing Support: NYSE Content Update
[Picked up by 1121 media titles]
2026-11-06 22:06
Cision Report Reveals the Consumer Trends Hidden Between Search, Social, and AI
[Picked up by 1105 media titles]
2026-11-09 23:00
Overstory Launches Integrated AI Platform to Deliver First Living Model of Grid Risk
[Picked up by 1083 media titles]
2026-11-03 22:00Most Read
Home Companion Robot Mobo to Debut Globally and Open Pre-orders as AiMOGA Showcases Its Robot Family at the 2026 OMODA & JAECOO International User Summit
2026-11-07 13:49
25933
ZD Energy Unveils Overseas Smart Energy Solutions in Thailand, Leveraging Local Manufacturing and Scenario-Based Capabilities to Support the Country's Energy Transition
2026-11-06 22:12
14837
SILVERSEA MARKS HISTORIC OPENING OF THE CORMORANT AT 55 SOUTH, THE SOUTHERNMOST HOTEL ON EARTH, OFFERING A NEW GATEWAY TO ANTARCTICA
2026-11-07 01:05
14355
OceanaGold Reports Third Quarter 2026 Results
2026-11-05 06:52
14177